Codexis Correlations
CDXS Stock | USD 2.99 0.12 3.86% |
The current 90-days correlation between Codexis and C4 Therapeutics is 0.37 (i.e., Weak diversification). The correlation of Codexis is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak. If the correlation is 0, the equities are not correlated; they are entirely random.
Codexis Correlation With Market
Poor diversification
The correlation between Codexis and DJI is 0.6 (i.e., Poor diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Codexis and DJI in the same portfolio, assuming nothing else is changed.
Moving together with Codexis Stock
0.62 | DNA | Ginkgo Bioworks Holdings | PairCorr |
0.66 | PFE | Pfizer Inc Aggressive Push | PairCorr |
0.69 | INBX | Inhibrx Biosciences, | PairCorr |
Moving against Codexis Stock
0.38 | BMY | Bristol Myers Squibb | PairCorr |
0.36 | VALN | Valneva SE ADR | PairCorr |
0.33 | ERNA | Eterna Therapeutics | PairCorr |
0.31 | DYAI | Dyadic International | PairCorr |
0.4 | PCRX | Pacira BioSciences, | PairCorr |
0.32 | ICUCW | LMF Acquisition Oppo | PairCorr |
0.5 | AMPH | Amphastar P | PairCorr |
0.36 | ANIK | Anika Therapeutics | PairCorr |
Related Correlations Analysis
Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Codexis Stock performing well and Codexis Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Codexis' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
---|---|---|---|---|---|---|---|---|---|---|
CCCC | 5.61 | 0.96 | 0.18 | 1.09 | 4.83 | 13.64 | 26.60 | |||
CDNA | 2.66 | 0.18 | (0.02) | (1.83) | 3.63 | 5.35 | 16.89 | |||
ERAS | 4.03 | 0.53 | 0.04 | (0.94) | 4.70 | 7.09 | 40.51 | |||
GBIO | 4.37 | 0.35 | 0.00 | (0.46) | 4.76 | 8.57 | 35.59 | |||
PSNL | 3.44 | 1.28 | 0.25 | (3.39) | 3.04 | 7.91 | 31.34 | |||
RPTX | 2.81 | 0.95 | 0.17 | (1.89) | 2.37 | 7.75 | 26.67 | |||
VCYT | 1.65 | (0.23) | 0.00 | 1.66 | 0.00 | 2.98 | 8.25 |
Codexis Corporate Management
Sriram MBA | Chief Officer | Profile | |
Georgia Erbez | Chief Officer | Profile | |
MBA Taylor | VP CFO | Profile | |
Asli Aras | VP Devel | Profile | |
Margaret JD | General Officer | Profile | |
John Schiffhauer | Senior Property | Profile |